A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes

What Was Tested

The trial (phase 2) is built around Tirzepatide and Eloralintide.

Participation in the study will last about 64 weeks.

It had ten arms (groups): one (experimental), one (experimental), one (experimental), one (experimental) and one (experimental).

Participants will receive LY3841136 subcutaneously (SC).

Participants will receive LY3841136 SC.

Participants will receive LY3841136 SC.

The registry classes the interventions as drug.

Who Took Part

367 actual participants took part.

It was open to people of any sex aged from 18 years up to 75 years.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: Have a Body Mass Index (BMI) of ≥27 kilograms per square meter (kg/m²). Have Type 2 Diabetes.

The full record lists 4 inclusion and 18 exclusion criteria; among the exclusions: have a history of severe hypoglycemia or hypoglycemia unawareness within the last 6 months prior to screening; have an on-going or history of bradyarrhythmia and/or sinus bradycardia; have any of the following cardiovascular conditions within 6 months prior to screening:.

How the Study Was Run

Design: randomized, parallel-group and double-blind.

Because people in this Tirzepatide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Groups ran in parallel: each of the participants stayed in one arm throughout.

Blinding on both sides kept the participants and researchers unaware of who received Tirzepatide.

Those kept unaware of assignments: participant and investigator.

It started in 2024-09-20 with completion listed for 2026-07-01.

It ran at 52 sites in United States (48) and Argentina (4).

Its stated primary purpose is treatment.

What Was Measured

The main thing measured (primary outcome): Percent Change from Baseline in Body Weight (time frame: Baseline, Week 48).

It also tracked 6 secondary outcomes, for example Change from Baseline in Body Weight, Change from baseline in Hemoglobin A1c (HbA1c) and PK: Maximum Concentration (Cmax) of LY3841136.

What This Means in Plain Language

Put simply, this is a phase 2, randomized trial of Tirzepatide and Eloralintide in 367 people.

The trial is marked completed; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Tirzepatide compound page and the Eloralintide compound page, all human trials.